Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA)’s traded shares stood at 0.67 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $0.24, to imply an increase of 5.08% or $0.01 in intraday trading. The SNOA share’s 52-week high remains $1.02, putting it -325.0% down since that peak but still an impressive 50.0% since price per share fell to its 52-week low of $0.12. The company has a valuation of $4.63M, with an average of 2.42 million shares in intraday trading volume over the past 10 days and average of 4.90 million shares over the past 3 months.
Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) trade information
After registering a 5.08% upside in the last session, Sonoma Pharmaceuticals Inc. (SNOA) has traded red over the past five days. The 5-day price performance for the stock is -3.20%, and -36.13% over 30 days. With these gigs, the year-to-date price performance is 34.15%. Short interest in Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) saw shorts transact 0.7 million shares and set a 0.18 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sonoma Pharmaceuticals Inc. (SNOA) estimates and forecasts
Looking at statistics comparing Sonoma Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Sonoma Pharmaceuticals Inc. (SNOA) shares are 65.75% up over the last 6 months, with its year-to-date growth rate higher than industry average at 47.37% against 19.70%. The rating firms project that company’s revenue will grow 33.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 3.98M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 4.39M.
SNOA Dividends
Sonoma Pharmaceuticals Inc. has its next earnings report out on 2024-Nov-11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA)’s Major holders
Sonoma Pharmaceuticals Inc. insiders hold 2.11% of total outstanding shares, with institutional holders owning 2.29% of the shares at 2.34% float percentage. In total, 2.29% institutions holds shares in the company, led by CITADEL ADVISORS LLC. As of 2024-06-30, the company held over 0.2 million shares (or 1.2504% of shares), all amounting to roughly $41412.0.
The next major institution holding the largest number of shares is GEODE CAPITAL MANAGEMENT, LLC with 86644.0 shares, or about 0.5551% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $18385.0.
We also have Fidelity Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund as the top two Mutual Funds with the largest holdings of the Sonoma Pharmaceuticals Inc. (SNOA) shares. Going by data provided on Jun 30, 2024 , Fidelity Extended Market Index Fund holds roughly 79.95 shares. This is just over 0.42% of the total shares, with a market valuation of $19347.0. Data from the same date shows that the other fund manager holds a little less at 4.97, or 0.03% of the shares, all valued at about 1203.0.
